Comparative Pharmacology
Head-to-head clinical analysis: BENZNIDAZOLE versus FEXINIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZNIDAZOLE versus FEXINIDAZOLE.
BENZNIDAZOLE vs FEXINIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Category C
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."